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Although themechanisms are largely unidentified, the chronic or intermittent hypoxic patterns occurring with respiratory diseases,
such as chronic pulmonary disease or obstructive sleep apnea (OSA) and obesity, are commonly associatedwith glucose intolerance.
Indeed, hypoxia has been widely implicated in the development of insulin resistance either via the direct action on insulin receptor
substrate (IRS) and protein kinase B (PKB/Akt) or indirectly through adipose tissue expansion and systemic inflammation. Yet
hypoxia is also known to encourage glucose transport using insulin-dependentmechanisms, largely reliant on themetabolic master
switch, 5󸀠 AMP-activated protein kinase (AMPK). In addition, hypoxic exposure has been shown to improve glucose control in type
2 diabetics. The literature surrounding hypoxia-induced changes to glycemic control appears to be confusing and conflicting. How
is it that the same stress can seemingly cause insulin resistance while increasing glucose uptake? There is little doubt that acute
hypoxia increases glucose metabolism in skeletal muscle and does so using the same pathway as muscle contraction. The purpose
of this review paper is to provide an insight into the mechanisms underpinning the observed effects and to open up discussions
around the conflicting data surrounding hypoxia and glucose control.
1. Introduction
Type 2 diabetes is a metabolic disease categorized, primarily,
by reduced insulin sensitivity, 𝛽-cell dysfunction, and ele-
vated hepatic glucose production [1]. Insulin resistance is
widely accepted as the starting point for the progression from
glucose intolerance to overt type 2 diabetes.Therefore under-
standing the underlining mechanisms of insulin resistance
pathophysiology is of great importance to the development
of novel and effective treatments.
Peripheral insulin resistance represents a decrease in
insulin-dependent glucose transport in insulin responsive
tissues [2], which can be the product of defects at both the
insulin receptor and/or postreceptor signaling [3]. Inflamma-
tion [4–7], hyperglycemia [8, 9], hyperinsulinemia [10, 11],
hyperlipidaemia [12, 13], and hypoxia [14–16] have all been
linked to the development of insulin resistance and type 2
diabetes. Indeed, hypoxia has been widely implicated in the
development of insulin resistance either via the direct action
on insulin receptor substrate (IRS) [17] and protein kinase
B (PKB; also known as Akt) [18, 19] or indirectly through
adipose tissue expansion [20] and systemic inflammation [21,
22]. However, we demonstrated that acute hypoxic exposure
increases two-compartment models of insulin sensitivity
(𝑆
𝐼
2∗) in human type 2 diabetics [23] with Lecoultre et al.
[24] showing that ten nights of moderate hypoxic exposure
improved insulin sensitivity in obese males, as measured by
the 2-step hyperinsulinemic-euglycemic clamp method.This
data highlights some of the controversy over the role hypoxia
plays in glucose control and metabolism. Interestingly, the
same work showed that muscle expression of Akt and IRS1
was not affected by the hypoxic treatment [24].
The purpose of this review is to consider the literature
while providing roles for hypoxia in causing insulin resistance
and glucose intolerance. Furthermore, this reviewwill discuss
hypoxia’s apparent dual ability to increase glucose transport
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activity acutely in skeletal muscle, using a pathway indepen-
dent of insulin, and dissect why hypoxia is also implicated
in insulin resistance. Providing a greater understanding of
the metabolic responses to hypoxia has genuine clinical
relevance andmay open up future therapeuticmethods in the
treatments of glucose intolerance and type 2 diabetes.
2. The Evidence Surrounding Hypoxic-Induced
Insulin Resistance
The observation that insulin resistance and glucose intoler-
ance are positively correlated with hypoxia originates from
studies by Strohl et al. in 1994 [25]. These authors suggested
that sleep apnea was independently associated with body
mass index (BMI) and insulin dysregulation [25].The chronic
or intermittent hypoxia patterns occurring with respiratory
diseases, such as chronic pulmonary disease or obstructive
sleep apnea (OSA), are commonly cited as potential causes of
glucose intolerance [26–28], an early indication of a disrup-
tion in normal glycemic control.The link between respiratory
diseases and insulin resistance is complex. Oltmanns et al.
[16] clearly showed that glucose infusion rates are reduced
in response to a 30-minute period of sustained hypoxia
(oxygen saturations levels ∼75%). The authors attribute this
to a sympathoadrenal-induced epinephrine release, resulting
in increased hepatic glucose production and a reduction in
glucose disposal at insulin sensitive peripheral tissue [16].
In addition, epinephrine has been shown to inhibit insulin-
stimulated glucose uptake in rat skeletal muscle by reducing
glucose phosphorylation [29]. The hypoxic stimulus used
in Oltmanns et al. [16] work is likely to have increased
hepatic glucose appearance [30] in an attempt to offset a
change in peripheral tissue fuel utilization towards glucose
metabolism.The consequencewould therefore be a reduction
in dextrose infusion rates [16] and a decrease in insulin
mediated glucose uptake [29]. Indeed, epinephrine causes
GLUT-4 translocation yet inhibits insulin mediated glucose
disposal skeletal muscle [31]. Thus the responses described
might reflect a transient change in metabolic processes and
not chronic changes in insulin resistance.
Brooks et al. showed that insulin concentrations were
elevated in healthy individuals upon arrival to high altitude
(4,300 metres) [32], suggesting that hypoxia may cause
glucose intolerance or at the very least disrupt glucose
metabolism. However this is hard to conclude without access
to c-peptide measures, which were not presented in this
work [32]. Furthermore, the rise in blood insulin values may
actually be a product of reduced insulin action rather than
decreased glucose uptake. In more recent work, Louis and
Punjabi [33] demonstrated a reduction in one-compartment
models of insulin sensitivity (𝑆
𝐼
) and insulin secretion in
response to 5 hours of intermittent hypoxia, a treatment used
to replicate OSA. In this study it was suggested that increased
sympathetic nervous activity, in response to intermittent
hypoxia, decreased glycogenesis, increased glycolysis, and
diminished the ability of glucose to stimulate its own uptake
and disposal [33, 34], which is a very confusingmessage. Yet if
we unpick this, it may provide some clarity to the underlining
metabolic response to hypoxia. We suggest that hypoxia
stimulates a stress pathway for glycolysis while blocking
insulin facilitated glucose uptake, providing a reason for the
reduction in glycogenesis seen in the work of Louis and
Punjabi [33]. However, this would not explain the decrease in
the ability of glucose to stimulate its own transport, measured
in Louis and Punjabi [33] work as glucose effectiveness (𝑆
𝐺
).
However, 𝑆
𝐺
is a mixed parameter that measures the ability
of glucose to affect its own transport by mass action at
basal insulin concentrations and is therefore dependent, to
an extent, on insulin.
In other reports insulin resistance increases with hypoxia
in genetically leptin deficient obese mice [15], respiratory
conditions [35], and healthy humans [14, 36]. However,
a closer look at the underlining data from these reports
is informative and helps unpick more detail around the
response of different models of hypoxia. For example, the
increase in insulin resistance noted in the Polotsky et al. [15]
study, which used obese, leptin deficientmice, was completely
abolished by acute leptin replacement. Leptin, an adipose
tissue peptide hormone, interacts with skeletal muscle [37],
increasing fatty acid oxidation, and reduces intramuscular
stores of triglycerides [38] while improving insulin action
[39]. There is evidence to show that a decrease in secondary
lipid products, ceramide, diglyceride, and long-chain fatty
acyl CoA can reduce the inhibitor effect of fats on Akt
mediated insulin signaling in skeletal muscle (reviewed [40]).
Using the typically regarded “gold standard” assessment
of glucose tolerance (euglycemic-hyperinsulinemic clamp),
Larsen et al. [41] found that insulin sensitivity decreased sig-
nificantly in response to 2 days of altitude exposure (4559m;
∼12%O
2
) with a reduction in glucose infusion rates to achieve
euglycemia, from 9.8 (1.1) to 4.5 (0.6)mg⋅kg−1⋅min−1 (P <
0.05). The same work did, however, show improvements in
insulin action with altitude acclimatisation (7-day exposure)
[41] suggesting a haemostatic balance between insulin secre-
tion, insulin action, and glucose disposal rates.
From a cellular mechanistic point of view, hypoxia seems
to induce insulin resistance in insulin sensitive tissue through
the suppression of total Akt during basal conditions and
with IGF-1 stimulation in C2C12 skeletal muscle cells [42].
Low oxygen treatment of C2C12 cells in vitro inhibits the
PI3-kinase/Akt pathway by reducing IGF-I receptor (IGF-IR)
sensitivity to growth factors [19], suggesting that hypoxiamay
interfere directly with key signaling transduction pathways
in skeletal muscle. In addition, the same work showed that
pGSK3𝛼S21, pGSK3𝛽S9, total GSK, pAktt308, pAkts473, and
total Akt were all reduced following 48 hours of differenti-
ation in C2C12 while IRS-1 and IRS-2 were unchanged under
severe hypoxic treatment (O
2
∼ 0.5%) [19]. This again sug-
gests that hypoxia alters insulin signaling at a postreceptor-
intracellular level and/or via an indirect action on IGF-
1 receptor. All of this data taken together demonstrates
that hypoxia, at least in in vitro models, has the ability
to alter insulin signaling of IRS downstream. It is worth
mentioning that the relevance of culture models to whole
body physiological responses must be read with a degree of
caution as the level of hypoxia (i.e., O
2
∼ 0.5–5%) commonly
used in vitro work is unlikely to be seen at the tissue level of
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skeletal muscle in humans subjected to whole body hypoxia
(i.e., O
2
∼ 12–15%). However, phosphorylation of Akts473
and GSK-3𝛽s9, obtained from vastus lateralis using standard
muscle biopsy techniques, was decreased in chronic obstruc-
tive pulmonary disease (COPD) patients presenting with
hypoxemia (resting arterial PO
2
= 57.0 (1.0)mmHg) [43].This
evidence suggests that chronic hypoxemia seen in disease
conditions may be involved in the progression of insulin
resistance. However, these findings were not supported in
skeletal muscle extracted from C57BL/6J mice treated with
10% O
2
for 4 weeks [44]. Interpretations from human work
are alsomixedwith Etheridge et al. [45] showing no change in
pAkts473 during hypoxia while D’Hulst et al. showed that 11%
inspired O
2
reduced pAkts473 [46]. The difference between
these studies may be explained by the basal nutritional status
of the subjects. Etheridge and colleagues [45] examined their
subjects in a fasted state, whereas those in D’Hulst and
colleagues study [46] consumed a meal 40 minutes prior to
the start of the experimental trial.
Lastly, whole body hypoxic treatment seen in in vivo
research is likely to affect a variety of tissue types, not just
skeletal muscle. Obesity is characterized by adipose tissue
expansion that results in pockets of localised tissue hypoxia
in the most affected areas. In addition, there is evidence
that localised hypoxia seen in adipose tissue may result
in systemic metabolic dysfunction seen in different tissue
types, further highlighting the complexity of the issue. For
this reason the effects of hypoxia on fat tissue have been
widely researched. In an attempt to isolate the effects of
hypoxia on adipocytes, Regazzetti et al. [47] treated 3T3-
L1 cells with 1% O
2
and showed that Akt, pAS160 content,
and glucose transport rates were all decreased under these
conditions and that this stress further inhibited insulin
signaling and glucose uptake in response to insulin treatment
[47].Thus the response of whole bodymetabolism to hypoxia
may be a systemic condition. Nevertheless, hypoxia clearly
alters metabolism and affects intracellular signaling of tissues
which is likely to serve the goal of reducing energy consuming
processes (i.e., glycogen formation and protein synthesis) and
upregulate ATP producing (i.e., glycolysis) and cell survival
mechanisms.
3. Hypoxia Stimulates Glucose Uptake
Independent of the Actions of Insulin
Insulin and contractile activity stimulate glucose disposal
in skeletal muscle using separate, independent signaling
pathways [48] with insulin mediated via Akt-AS160 and
contraction via AMPK-AS160. Hypoxia also activates glu-
cose transport using the same signaling pathway as that of
contractile activity [49] (Figure 1). Indeed, glucose transport
has been shown to be additive when either hypoxia or
contractile activity is coupled with insulin, whereas hypoxia
and contractile activity are not [49, 50]. The ability of
hypoxia to stimulate glucose disposal, independently of
contractile activity, has been documented in both animal
[49, 51] and in vitro work using isolated human muscle tissue
[48, 50].
In 1958 Randle and Smith published data showing that
hypoxia, induced via the chemical inhibition of oxidative
metabolism, resulted in a loss of cellular potassium (K+),
inhibition of active K+ uptake, coupled with stimulation of
ATP-sensitive K+ channels, an increase in cellular ATP/AMP
ratio, and ultimately an increase in extracellular K+ levels
[52, 53].These ion changes lead to membrane depolarisation,
opening of voltage-gated Ca2+ channels, and an increase in
SR Ca2+ release in a manner similar to muscle contraction.
Hypoxia is known to reduce oxygen availability, inhibit
mitochondrial respiration [54], and increaseAMP :ATP ratio
[55], resulting in increased cytolytic AMP availability and
greater AMP binding capacity to the 𝛾 regulatory subunit,
activation of AMPK [56], and stimulation of glucose trans-
port [49].
It is clear that hypoxia (at least during the stress)
encourages glucose uptake in skeletal muscle via AMPK and
Ca2+-dependent mechanisms. Evidence shows that Ca2+ can
activate glucose uptake in a calmodulin-dependent protein
kinase (CaMKK)/AMPK-dependent manner [57] identical
to mechanisms responsible for contraction induced glucose
uptake inmuscle [48, 49], although elevations in intracellular
Ca2+ levels may also provoke AMPK-independent glucose
transport as glucose transport activity is increased during
subcontraction increases in muscle Ca2+ when stimulated
with caffeine [56]. Activation of glucose uptake with hypoxia
is facilitated by an increase in the activation of GLUT-
1 preexisting in the cell membrane [54] while stimulating
translocation of intracellular GLUT-1 and GLUT-4 to the
sarcolemma [49, 54].
AMPK is essential for hypoxia-induced glucose transport
[58]. Using AMPK𝛼2 deficient rodents (Tg-KD1), Mu et al.
[58] showed that glucose transport was completely blocked
under hypoxia when compared to wild-type counterparts.
Furthermore, the hypoxia-induced increase in membrane
bound GLUT-4 content was reduced in the same Tg-KD1
mice [58]. These findings have been extended into human
work, with Wadley et al. [59] showing that AMPK𝛼2 activ-
ity and AMPK𝛼 Thr172 phosphorylation were significantly
increased during exercise in hypoxia when compared to
the same relative exercise intensity in normoxic conditions.
The rate of glucose disappearance was also found to be
significantly higher in the hypoxic trial, suggesting that
hypoxia, when combined with exercise, has a greater effect
on AMPK activity and glucose transport over exercise alone
[59] and that hypoxia mediates glucose uptake via a pathway
dependent (partly) on AMPK in humans.
Much of the work discussed above is in cell culture
models or animal work, yet the findings from a whole body
perspective seem to align well with this data. Using isotope
methodology Brooks et al. [32] concluded that altitude
acclimatisation (4300m) increased glucose disappearance
(𝑅
𝑑
) and metabolic clearance rates (MCR) during both
exercise and resting states when compared to sea-level values.
Interestingly, insulin concentrations were unchanged from
prealtitude levels [32], suggesting an increase in contraction-
stimulated glucose transport or improved insulin sensitivity
at altitude. In support Johnson et al. [61] demonstrated that
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Figure 1: Insulin and contraction signaling pathways during GLUT-4 recruitment and translocation. Adapted from Mackenzie and
Elliott [60]. IRS, insulin receptor substrate; PI3-K, class IA phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate;
PIP3, phosphatidylinositol 3,4,5-trisphosphate; PDK1, phosphoinositide-dependent protein kinase-1; Akt, serine/threonine protein kinase;
AS160, 160 kDa Akt substrate; GLUT-4, glucose transporter 4; GSV, GLUT-4 storage vesicle; Rab-GAP, Rab-GTPase-activating protein;
Rab-GDP, guanosine-50-diphosphate-loaded Rab; Rab-GTP, guanosine-50-triphosphate-loaded Rab; CaMKK, Ca2+/calmodulin-dependent
protein kinase kinase; LKB1, serine/threonine kinase 11; STRAD, putative kinase; MO25, mouse protein 25/scaffold protein; AMPK, 5󸀠-
monophosphate-activated protein kinase;Thr172, phosphorylatedAMPK𝛼 at threonine 172; AMP, adenosinemonophosphate; ATP, adenosine
triphosphate; P, phosphorylated site.
acute altitude exposure (2–40 hr) resulted in progressive
hypoglycemia, which was attributed to increased glucose
clearance and oxidation, which was confirmed by Cooper
et al. [62]. Using an oral glucose tolerance test, Lee et al.
[63] showed that high altitude exposure (3 days) significantly
improved glucose tolerance in sea-level natives and in type 2
diabetics. Prior hypoxic exposure is also known to increase
two-compartment models of insulin sensitivity [23] with
acute intermittent hypoxia shown to improve glucose control
in patients with type 2 diabetes [64].
A study by Forbes, in 1936, was one of the first to suggest
that altitude could alter the manner in which glucose is
handled by health sea-level residents [65]. This work showed
that blood glucose clearance was increased during an OGTT
administrated at high altitude. Following this work, research
has not only confirmed Forbes [65] conclusions but looked
to extend them by showing that long-term exposure to
simulated or actual altitude results in (1) reduced fasting
plasma glucose concentrations [66–69] and (2) elevated
glucose clearance rates during an intravenous glucose load
[66, 68].
A recent review concluded that long-term exposure to
altitude results in improved glycemic control and lower
prevalence of obesity and diabetes [70]. It is generally recog-
nised that high altitude natives have a reduced prevalence
of type 2 diabetes [67, 71, 72] while the same population
also displays lower glucose concentrations (50.6 (3.7)mg/dL)
compared to sea-level residents (73.4 (4.0)mg/dL) when
monitored during ∼12-hour period [73]. Despite having a
high prevalence of obesity (BMI ≥ 30 kg/m2) rural Aymara
natives (living at altitudes 2050–4250m) are also known
to be at a reduced risk of developing type 2 diabetes [72].
These authors attributed this finding to near normal insulin
values (mean (SD); 9.3 (10.2) 𝜇U/mL) and low levels of insulin
resistance (HOMAIR 1.8 (2.4)) [72].
Studies elsewhere have shown that long-term altitude
exposure is linked with low glucose and insulin concen-
trations [74, 75]. Ge et al. [76] concluded that Tibetan
natives exhibit genetic modification (namely, PPARA, encod-
ing PPAR𝛼) that increases glycolysis and decreases hepatic
gluconeogenesis and free fatty acids. The authors further
suggest that these adaptations may help to reduce diabetic
and obesity risk [76]. Indirect evidence also shows inverse
correlations between altitude natives and the risks of diabetes
[77].
3.1. Insulin Resistance Seen with Hypoxia May Merely Reflect
the Use of a Separate Preferential Pathway for Glucose Uptake.
The literature surrounding hypoxic induced changes in
glycemic control, insulin resistance, and type 2 diabetes
may appear as confusing and conflicting. How is it that
hypoxia can seemingly cause insulin resistance while at the
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same time stimulating glucose uptake? The answer may be
attributed to the duration of stress (minutes versus days), the
host (i.e., altitude natives versus obese type 2 diabetics), the
nutritional status of the host, the model under investigation
(cell culture versus whole body), the degree of adaptation
to the conditions, and the measurement methods under use
(hyperinsulinemic-euglycemic clamp during hypoxia), if we
can put all of these matters to one side for the time being and
remember that hypoxia is stress and that, under such con-
ditions, respiring tissue seems to switch to a stress mediated
pathway acting independently, in this context, to insulin.This
has been demonstrated indirectly through the suppression
of insulin action [14, 16] and insulin secretion with hypoxic
treatment [78], while, at the same time, encouraging glucose
uptake [32, 49]. We suggest that under hypoxic condi-
tion a preferential Ca2+/AMPK-dependent pathway may be
upregulated to maintain ATP production (glycolysis) and
reduce ATP consuming mechanisms (protein and glycogen
synthesis). This is partly supported by the literature that
shows that hypoxia and exercise stimulate glucose uptake via
AMPK-AS160 [58, 79] while insulin acts through Akt-AS160
[80–82] mediated pathways. Comparisons with exercise are
used, as this stimulus is known to activate glucose uptake
using the same mechanisms associated with hypoxia.
Hypoxia has been shown, in cell lines, to impair IRS-1
[47], Akt, and PI3-kinase activity [19, 42], yet the same stress
increases glucose uptake, intracellular Ca2+ levels, CaMKK,
AMPK-AS160, and GLUT-4 muscle content. In support,
whole body experimental work would suggest that hypoxia
induces insulin resistance while also stimulating glucose
disposal.This reviewwill now try to explain these contrasting
views while proposing a working hypothesis as to the role of
hypoxia in glucose metabolism.
Firstly, the findings fromwhole body studies that hypoxia
causes insulin resistance may be the product of increased
insulin release combined with a decrease in insulin action
at the site of insulin sensitive target tissue. Indeed, elevated
circulating insulin concentration and perceived insulin resis-
tance with hypoxic treatment [83] are a finding that has some
support. In addition, hypoxia is known to encourage insulin
synthesis and release by pancreatic 𝛽-cells [84], creating an
acute or chronic physiological state resulting in blood insulin
accumulation and perhaps perceived insulin resistance. This
combinedwith decreased insulin-stimulated glucose disposal
and insulin signaling is likely to result in such conclusions.
Further, the introduction of exogenous insulin, which is
implicit in the hyperinsulinemic-euglycemic clamp method,
may further aggravate the problem. Hyperinsulinemia has
been demonstrated to inhibit IRS-1/Akt activity in vitro [11]
and cause insulin resistance in vivo [10, 17, 85, 86]. Thus
the use of the two-step hyperinsulinemic-euglycemic clamp
which delivers low insulin (20mU⋅m−2⋅min−1 for 180min)
followed by high insulin dose (80mU⋅m−2⋅min−1 for 120min)
[24] may be a better approach to assessing insulin sensitivity
in insulin resistant/obese populations under additional envi-
ronmental hypoxia. Importantly, Lecoultre et al. [24] work
measured insulin sensitivity under normoxic conditions both
before and after the ten-day treatment. Thus the clamp
method here was employed following low oxygen treatment,
rather than during hypoxic conditions.
Here we suggest that combining hypoxia with insulin
accumulation, through its exogenous introduction and/or
decreased insulin action, would indicate that the use of
clamp methods is not necessarily an appropriate model for
assessing insulin sensitivity under nonsteady state conditions
such as exercise or hypoxia. Indeed, the introduction of
exogenous insulin with the hyperinsulinemic-euglycemic
clamp and a decrease in insulin signaling activity [17] due
to heavier reliance on contraction-stimulated glucose uptake
may merely reflect a shift towards a preferential pathway for
glucose uptake resulting in plasma insulin accumulation.
There may also be some intracellular cross-talk between
the two prominent regulatory pathways involved in con-
trolling glucose uptake under hypoxic conditions which
results in upregulation of AMPK-AS160 that coexists with
a reduction in insulin mediated glucose transport. There
is certainly some good evidence that hypoxia may cause
insulin resistance; however it is proposed that this may
be a product of a competition between pathways (i.e., a
preferential use of the AMPK pathway under hypoxic stress)
with a subsequent decrease in insulin signaling rather than
insulin resistance per se. This is supported by the direct inhi-
bition of insulin stimulated glucose transport with treatment
of the calmodulin antagonist N-(6-aminohexyl)-5-chloro-
1-naphthalenesulfonamide (W-7) [87]. Calmodulin (CaM)
is a calcium-binding protein that modifies target proteins
[88] such as AMPK [89]. In addition this Ca2+/calmodulin
complex is considered to be involved in hypoxic induced
glucose uptake [90] with AMPK activation increased with
the overexpression of Ca2+/calmodulin-dependent protein
kinase (CaMKK) [89]. In addition, the downregulation of
CaMKKusingRNA interference inhibits AMPKactivity [89],
implicating CaMKK in AMPK regulation and glucose uptake
[48, 56, 91, 92].
Hypoxia increases intracellular free Ca2+ [49] and sub-
sequently CaMKK [90] with the ensuing calcium signaling
directly inhibiting insulin-stimulated glucose transport. The
proposedmechanisms involved in this inhibition are detailed
in Figure 2(a). Youn et al. [87] showed that the effects of W-
7 treatment on glucose transport were additive with hypoxia
and that the same treatment reduced insulin mediated glu-
cose transport in skeletal muscle. Furthermore, a fivefold
increase in insulin concentration was required to produce
a half-maximal stimulation in glucose transport [87]. All of
this data combined indicates that hypoxia-induced glucose
transport is not hindered by W-7 treatment and that free
intracellular Ca2+ may directly or indirectly inhibit insulin
signaling. This data suggests that the upregulation of glucose
uptake by hypoxia may result in insulin accumulation sys-
temically, by the effect of reduced processing of insulin into
insulin fragments by insulin sensitive tissues.The latter point
is important as this may lead to the conclusion that hypoxia
causes a reduction in insulin action and results in glucose
intolerance due to plasma insulin accumulation.
Further evidence of the regulatory pathways that affect
glucose transport work independently of each other, yet
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Figure 2: Proposed communication between hypoxia- and insulin-stimulated glucose transport mechanisms. (a) displays the proposed
hypoxia-induced Ca2+/CaMKK inhibition on insulin signaling and insulin-stimulated glucose transport. Glucose transport is facilitated via
an AMPK-dependent mechanism in response to hypoxia despite decreased Akt activity. (b) Glucose transport mechanisms in response to
insulin. (b) also displays Akt mediated AMPK phosphorylation at Ser485/491 [93] resulting in AMPK inhibition.
having the ability to communicate with one another, comes
from experiments with 5-aminoimidazole-4-carboxamide
ribonucleoside (AICAR), which activates AMPK while
inhibiting insulin-stimulated glucose transport in 3T3-L1
adipocytes [94]. Incubating C2C12 skeletal muscle cells or
rat extensor digitorum longus (EDL) muscle with insulin
increases phosphorylation of AMPK at S485/491 [95].
Phosphorylation of AMPK at S485/491 directly inhibits
AMPK activity. Indeed, insulin stimulation of Akt results in
pAMPKS485/491, leading to a reduction in AMPK activity [93]
(Figure 2(b)). This phosphorylation can prevent subsequent
activation of AMPKTh172 by LKB1 and that pAMPK at
S485/491 by insulin reduces the interaction between AMPK
and LKB1 [96] suggesting that insulin inhibition of AMPK
occurs upstream and that insulin, via the activation of Akt,
may directly interfere with AMPK phosphorylation and
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activity [93], while presumably reducing AMPK-dependent
glucose uptake. Collectively, these data again suggest that a
potential cross-talk interplay between the Akt and AMPK
pathways may exist and that the downregulation of insulin
signaling by hypoxia reduces the Akt inhibitory effect on
pAMPKS485/491.
4. Concluding Remarks
Evidence that hypoxia leads to insulin resistance has been
widely published.There seems little doubt that acute hypoxia
interferes with insulin signaling/action in skeletal muscle.
Yet the same stress is also partnered with increased glucose
uptake in a largely insulin independent manner. In vivo
research presents data which is conflicting, some showing
improvements in insulin sensitivity while others suggesting
that hypoxia induces insulin resistance. At a cellular level,
there seems to be less controversy. Hypoxia increases glucose
uptake and activates Ca2+/AMPK mediated pathways in
response to low oxygen tension in both cell culture models
and ex vivo skeletal muscle. Yet, the same stress seems to
decrease receptor and postreceptor activity of key insulin
signaling intermediates. Firstly, we suggest that hypoxia does
indeed downregulate insulin signaling, at least in skeletal
muscle, and that a reduction in this pathway ultimately
results in insulin accumulation and results in the misleading
detection of insulin resistance, making the in vivomodelling
of insulin sensitivity under hypoxic conditions difficult,
particularly with the introduction of high physiological con-
centrations of exogenous insulin as associatedwith the hyper-
insulinemic clamp approach. It seems clear that the twomajor
pathways involved in glucose transport and metabolism in
skeletal muscle, insulin- and contraction-dependent mech-
anisms, work separately and that upon the application of
stress (i.e., hypoxia) cells shift towards a preferred AMPK-
dependent mechanism and away from insulin. This is merely
a working hypothesis but is not a new notion with Cartee
et al. [49] and Azevedo et al. [50] clearly demonstrating
that hypoxia activates the contraction-stimulated pathway to
facilitate glucose transport and that this occurs independent
of the actions of insulin.
It is important that we develop a better understanding
of glucose transport mechanisms and the causes of insulin
resistance as this has clear clinical applications. Furthermore,
it may be that hypoxia has a part to play in the therapeutic
treatment of type 2 diabetes rather than being implicated in
its progression. Conclusions from in vitrowork are important
but limited in application. At a whole body level, many of the
studies that demonstrate a link between insulin resistance and
hypoxia have done so while measuring this parameter under
low oxygen conditions, which, while being a valid approach
in terms of external validity, makes the modelling of insulin
sensitivity difficult. Thus developing new in vivo approaches
to modelling insulin sensitivity, such as the two-step clamp
method, may increase our understanding of the role hypoxia
plays in glucose transport and glycemic control. Glucose
effectiveness, asmeasured by the labelled intravenous glucose
tolerance test (IVGTT), quantifies the ability of glucose to
transport itself at basal insulin concentration.This technique
also separates glucose control into measures of hepatic
glucose production and disposition index and, as such, may
provide a useful approach to assessing the true effects of
hypoxia on insulin and hypoxic mediated glucose disposal.
The question of whether hypoxia causes insulin resis-
tance, or not, is a complex one. At a cellular level, the
evidence clearly shows that hypoxia increases glucose uptake
and that this coexists with an inhibition of insulin signaling.
The authors propose that under hypoxic conditions, at least
acutely, glucose transport is increased using cellular pathways
that operate independent of insulin thus given the impression
of insulin resistance. Given the current research, the authors
conclude that hypoxiamay decrease insulin signaling butmay
not induce whole body insulin resistance.
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